ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,431.60
-0.04%
US Tech 100
19,168.00
0.52%
Dow Jones
38,589.16
-0.15%
Brent Oil
82.095
-0.04%
Bitcoin
66,578.94
-0.09%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Arcellx Inc (ACLX) Quote

Arcellx Inc

Arcellx Inc (ACLX)

NASDAQ
54.41
-1.38
(-2.47%)
Closed June 16 4:00PM
Delayed by 15 minutes
54.41
0.00
(0.00%)
After Hours: 5:30PM
Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
54.41
Bid
52.31
Ask
60.44
Volume
352,296
53.725 Day's Range 56.09
30.74 52 Week Range 75.10
Market Cap
2.873B
Previous Close
55.79
Open
54.96
Last Trade
12
@
52.75
Last Trade Time
Financial Volume
$ 19,262,520
VWAP
54.6771
Average Volume (3m)
458,531
Shares Outstanding
52,796,618
Dividend Yield
-
PE Ratio
-40.64
Earnings Per Share (EPS)
-1.34
Revenue
110.32M
Net Profit
-70.69M

About Arcellx Inc

Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases.

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.arcellx.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
Arcellx Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker ACLX. The last closing price for Arcellx was $55.79. Over the last year, Arcellx shares have traded in a share price range of $ 30.74 to $ 75.10.

Arcellx currently has 52,796,618 shares outstanding. The market capitalization of Arcellx is $2.87 billion. Arcellx has a price to earnings ratio (PE ratio) of -40.64.

ACLX Latest News

More News

Form 4 - Statement of changes in beneficial ownership of securities

June 14 2024
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

June 12 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

May 24 2024
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

May 24 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 09 2024
Edgar (US Regulatory)

Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

-- The companies share design of global Phase 3 trial, iMMagine-3; will evaluate anito-cel in patients exposed to both an immunomodulatory (lMiD) drug and an anti-CD38 monoclonal antibody...

May 09 2024
Business Wire

Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

-- The companies share design of global Phase 3 trial, iMMagine-3; will evaluate anito-cel in patients exposed to both an immunomodulatory (lMiD) drug and an anti-CD38 monoclonal antibody...

May 09 2024
Business Wire

Arcellx Provides First Quarter 2024 Financial Results

Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today...

May 09 2024
Business Wire

Arcellx to Participate in Two Upcoming Investor Conferences

Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today...

May 07 2024
Business Wire

Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today...

April 04 2024
Business Wire
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
13.567.0009832841750.8558.6850.0248129854.41176048CS
41.482.7961458530152.9358.6849.9745280152.91271492CS
12-18.13-24.993107251272.5472.5447.8845853155.26053377CS
263.46.6653597333951.0175.147.8847509858.45709552CS
5215.3539.29851510539.0675.130.7454724847.7973235CS
15635.41186.3684210531975.16.03548004736.70111395CS
26035.41186.3684210531975.16.03548004736.70111395CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
KAVLKaival Brands Innovations Group Inc
$ 5.96
(338.24%)
70.99M
LRHCLa Rosa Holdings Corporation
$ 1.165
(90.61%)
40.6M
SVMHSRIVARU Holding Ltd
$ 0.227586
(49.24%)
276.03M
BRFHBarfresh Food Group Inc
$ 3.03
(38.36%)
247.31k
NNENano Nuclear Energy Inc
$ 9.37
(32.53%)
1.77M
NXLNexalin Technologies Inc
$ 0.89
(-35.52%)
3.93M
INABIN8bio Inc
$ 1.095
(-34.82%)
4.92M
QXOQXO Inc
$ 134.10
(-34.71%)
142.29k
GANXGain Therapeutics Inc
$ 1.24
(-34.39%)
3.09M
KYTXKyverna Therapeutics Inc
$ 9.52
(-34.07%)
4.31M
NVDANVIDIA Corporation
$ 131.88
(1.75%)
309.34M
SVMHSRIVARU Holding Ltd
$ 0.227586
(49.24%)
276.03M
KITTNauticus Robotics Inc
$ 0.1921
(19.69%)
165.83M
CRKNCrown Electrokinetics Corporation
$ 0.0582
(-21.35%)
136.77M
SQQQProShares UltraPro Short QQQ
$ 8.43
(-1.29%)
112.46M

ACLX Discussion

View Posts
Monksdream Monksdream 2 months ago
ACLX over $30
👍️0
Monksdream Monksdream 5 months ago
ACLX new 52 week high
👍️0
Monksdream Monksdream 5 months ago
ACLX new 52 week high
👍️0
Monksdream Monksdream 5 months ago
ACLX new 52 week high
👍️0
bandit007 bandit007 2 years ago
Going beast mode into next week.
👍️0
TheyWantYourShares TheyWantYourShares 2 years ago
Nice correction coming here. New IPO at 16… company is flush with capital/cash. Moves coming and getting in now will pay off big IMHO.


Got in on the drop @average: 13.12 … 2 and 3 days ago.


$ACLX


GLTA!!



-TWYS
👍️0
crudeoil24 crudeoil24 2 years ago
Net loss of $44M > no revenues! ( over 9 month period)

ACLX
👍️0
crudeoil24 crudeoil24 2 years ago
Arcellx Inc. ACLX, has set terms for its initial public offering, in which the Maryland-based biotechnology company, which is developing cancer treatments, looks to raise up to $140.25 million. The company said it is offering 8.25 million shares in the IPO, which is expected to price between $15 and $17 a share. With 33.54 million shares expected to be outstanding after the IPO, the expected pricing could value the company at up to $570.24 million. The stock is expected to list on the Nasdaq under the ticker symbol "ACLX." BofA Securities, SVB Leerink, Barclays and William Blair are the lead underwriters. The company recorded a net loss of $44.30 million on no revenue during the nine months ended Sept. 30, after a loss of $23.00 million on no revenue in the same period a year ago. Arcellx is looking to go public at a time of relative investor disdain for IPOs and biotechs, as the Renaissance IPO ETF IPO, -3.27% has plunged 37.2% over the past three months and the iShares Biotechnology ETF IBB, -1.39% has tumbled 19.8%, while the S&P 500 SPX, +0.31% has slipped 3.8%.
👍️0

Your Recent History

NASDAQ
ACLX
Arcellx
UNSW3
TRIPSETH
Trips
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved